Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
169.2 USD | +0.70% |
|
+0.68% | +9.18% |
Jul. 12 | AbbVie Submits FDA, EMA Applications for Upadacitinib to Treat Giant Cell Arteritis | MT |
Jul. 12 | AbbVie Seeks U.S., Europe OK of Rinvoq in Giant Cell Arteritis | DJ |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.18% | 299B | |
+61.53% | 848B | |
+33.93% | 627B | |
-3.66% | 363B | |
+15.06% | 318B | |
+11.25% | 234B | |
+15.36% | 225B | |
+15.67% | 179B | |
+2.47% | 167B | |
+2.02% | 125B |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- Transcript : AbbVie Inc. Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-15-2014 09